14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
FBLG vs VENU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, FibroBiologics, Inc. (FBLG) captures the overall head-to-head institutional edge over Venu Holding Corporation (VENU) on higher Unified Composite conviction (41.0/100 SELL vs. 42.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while VENU wins 3–2 across the 6-pillar growth and valuation breakdown. FBLG trades at $0.70 (N/M Forward P/E, 0.0% operating margin) versus VENU at $0.99 (N/M Forward P/E, -294.7% operating margin).
Composite vs. Pillar Nuance: While VENU currently prints a higher short-term Unified Composite Score (42.3/100 HOLD vs. FBLG 41.0/100 SELL), FBLG captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -294.7% operating margin) and revenue trajectory (+0.0% vs. +2.9% YoY).
Technical & Structure Timing Caution: FBLG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile VENU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FBLG vs VENU. Trailing 12-month operating profitability (FBLG 0.0% vs VENU -294.7%) and valuation multiples (FBLG N/M vs VENU N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Restaurants value chain with $58.3M market capitalization and -294.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FBLG vs VENU Key Questions & Quantitative Answers
As of Nov 20, 2026, FibroBiologics, Inc. (FBLG) captures the overall head-to-head institutional edge over Venu Holding Corporation (VENU) on higher Unified Composite conviction (41.0/100 SELL vs. 42.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while VENU wins 3–2 across the 6-pillar growth and valuation breakdown. FBLG trades at $0.70 (N/M Forward P/E, 0.0% operating margin) versus VENU at $0.99 (N/M Forward P/E, -294.7% operating margin). Composite vs. Pillar Nuance: While VENU currently prints a higher short-term Unified Composite Score (42.3/100 HOLD vs. FBLG 41.0/100 SELL), FBLG captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -294.7% operating margin) and revenue trajectory (+0.0% vs. +2.9% YoY). Technical & Structure Timing Caution: FBLG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile VENU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VENU leads the Growth & Scale pillar: FBLG posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VENU at +2.9% YoY revenue growth and +0.0% YoY earnings growth on $19M TTM revenue (16.4% gross margin, -294.7% operating margin). On trailing 12-month operating scale, FBLG generates N/A in USD-normalized revenue versus $19M for VENU. In operating R&D and SG&A reinvestment, FBLG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VENU.
VENU screens cheaper on headline valuation multiples. FBLG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VENU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBLG (-1696.9% ROE) versus VENU (-24.9% ROE) capital efficiency.
In options market volatility and institutional positioning, FBLG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-2.17β · 68% Vol realized risk). By comparison, VENU carries 76.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.72β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.